Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the presentation of initial safety data from the ongoing Phase 1 clinical trial evaluating the recommended dose, safety and...
Source: lelezard.com